MRD Dynamics Offer Valuable Prognostication During Ixazomib Maintenance for MM
Periodic assessment of measurable residual disease (MRD) dynamics may provide better prognostic value than MRD status assessed at a single ...
Getting Specific: Mass Spectrometry Provides Detail for Diagnosing and Monitoring Plasma Cell Disorders
Research scientists and some medical institutions have begun applying mass spectrometry (MS)–based techniques in the diagnosis and monitoring of plasma cell disorders ...
GPRC5D: A New Target for CAR T-Cell Therapy in MM
Results from an early trial of a chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor, class C, group 5, member D ...
Heavily Pre-Treated Patients with MM Respond to Cilta-Cel CAR T-Cell Therapy
Patients with MM who had received multiple prior therapies, including BCMA–targeting agents, and had progressive disease responded to treatment with cilta-cel, resulting in ...
EPd Triplet Therapy Boosts Survival in R/R MM Vs. Pd
Treatment with elotuzumab plus pomalidomide/dexamethasone resulted in a significant reduction in the risk of death compared with pomalidomide/dexamethasone in patients with...
National Cohort Study Suggests MGUS Increases Risk of Cardiovascular Diseases
With 8,189 patients with MGUS and 81,890 controls, the findings from this large sample size highlight the wide-ranging risks that come with MGUS ...
Insights Into the Burden of MM on Caregivers
A significant proportion of caregivers of patients with multiple myeloma (MM) experience substantial psychological distress and believe that their loved one’s disease is curable, according to study findings published in Blood Advances....
Subcutaneous Versus IV Daratumumab May Be a Preferred Treatment Choice in Patients With R/R MM
Subcutaneously administered daratumumab, the standard formulation used in clinical practice, was associated with a similar efficacy and safety profile as intravenous (IV) daratumumab but also had fewer infusion-related reactions and shorter administration time in this population...
Elranatamab Results in 61% ORR in Patients With R/R MM in Phase II Study
Elranatamab is a humanized bispecific antibody that targets BCMA-expressing MM cells and CD3-expressing T cells. ...
MajesTEC-1 Results Show Teclistamab Elicits Durable Responses in Patients With R/R MM
In patients with relapsed/refractory multiple myeloma (R/R MM), treatment with teclistamab, a humanized B-cell maturation antigen (BCMA) and CD3 bispecific antibody, resulted in deep responses that can be durable...
